279 related articles for article (PubMed ID: 24460345)
21. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer.
Balcan E; Demirkiran F; Aydin Y; Sanioglu C; Bese T; Arvas M; Akçay T; Cift T
Int J Gynecol Cancer; 2012 Sep; 22(7):1138-42. PubMed ID: 22914212
[TBL] [Abstract][Full Text] [Related]
23. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
24. Anti-Müllerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial cancer.
Dogan NU; Kerimoglu OS; Karabagli P; Pekin A; Yilmaz SA; Incesu F; Celik C
J Obstet Gynaecol; 2015 Feb; 35(2):178-82. PubMed ID: 25111828
[TBL] [Abstract][Full Text] [Related]
25. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
26. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
27. Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer.
Kanojia D; Garg M; Gupta S; Gupta A; Suri A
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):630-9. PubMed ID: 19190149
[TBL] [Abstract][Full Text] [Related]
28. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
Moolthiya W; Yuenyao P
Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
[TBL] [Abstract][Full Text] [Related]
29. Circulating prolactin levels and risk of epithelial ovarian cancer.
Clendenen TV; Arslan AA; Lokshin AE; Liu M; Lundin E; Koenig KL; Berrino F; Hallmans G; Idahl A; Krogh V; Lukanova A; Marrangoni A; Muti P; Nolen BM; Ohlson N; Shore RE; Sieri S; Zeleniuch-Jacquotte A
Cancer Causes Control; 2013 Apr; 24(4):741-8. PubMed ID: 23378139
[TBL] [Abstract][Full Text] [Related]
30. SPAG9 May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin.
Li C; Bai Y; Yan L; Zhang L; Zhang H; Li M; Zhao M; Gao Y; Zhao X
Gynecol Obstet Invest; 2016; 81(3):267-74. PubMed ID: 26334303
[TBL] [Abstract][Full Text] [Related]
31. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
Pradjatmo H; Pradjatmo H
Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
[TBL] [Abstract][Full Text] [Related]
32. Prediction of lymphovascular space invasion in patients with endometrial cancer.
Kim SI; Yoon JH; Lee SJ; Song MJ; Kim JH; Lee HN; Jung G; Yoo JG
Int J Med Sci; 2021; 18(13):2828-2834. PubMed ID: 34220310
[No Abstract] [Full Text] [Related]
33. Diagnostic Impacts of Serum CA-125 Levels, Pap Smear Evaluation, and Endometrial Sampling in Women with Endometrial Clear Cell Carcinoma.
Cetinkaya N; Selcuk İ; Ozdal B; Meydanli MM; Gungor T
Oncol Res Treat; 2016; 39(5):283-8. PubMed ID: 27173475
[TBL] [Abstract][Full Text] [Related]
34. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
35. Preoperative MRI and intraoperative frozen section diagnosis of myometrial invasion in patients with endometrial cancer.
Tanaka T; Terai Y; Ono YJ; Fujiwara S; Tanaka Y; Sasaki H; Tsunetoh S; Kanemura M; Yamamoto K; Yamada T; Ohmichi M
Int J Gynecol Cancer; 2015 Jun; 25(5):879-83. PubMed ID: 25950131
[TBL] [Abstract][Full Text] [Related]
36. Circulating adropin levels in patients with endometrium cancer.
Nergiz S; Altinkaya SO; Kurt Ömürlü İ; Yuksel H; Küçük M; Demircan Sezer S
Gynecol Endocrinol; 2015; 31(9):730-5. PubMed ID: 26172926
[TBL] [Abstract][Full Text] [Related]
37. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
38. The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma.
Modarres-Gilani M; Vaezi M; Shariat M; Zamani N; Nourizadeh R
Cancer Biomark; 2017 Aug; 20(2):135-141. PubMed ID: 28800309
[TBL] [Abstract][Full Text] [Related]
39. Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools.
Besso MJ; Montivero L; Lacunza E; Argibay MC; Abba M; Furlong LI; Colas E; Gil-Moreno A; Reventos J; Bello R; Vazquez-Levin MH
Oncol Rep; 2020 Sep; 44(3):873-886. PubMed ID: 32705231
[TBL] [Abstract][Full Text] [Related]
40. The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.
Abdalla N; Pazura M; Słomka A; Piórkowski R; Sawicki W; Cendrowski K
Ginekol Pol; 2016; 87(12):781-786. PubMed ID: 28098927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
